2017年3月6日星期一

A new method used to treat asthma

A new study published in the Journal of Allergy and Clinical Immunology investigates a potential new approach for the treatment of asthma. According to research using recombinant human proteins, asthma causes the individual's airway to become inflamed and narrower and produce additional mucus. The patient's breathing becomes difficult, and the result is a wheezing and coughing. It is estimated that 12% of people in the United States suffer from asthma, equivalent to about 25 million people.

There is a series of potential triggers for asthma. These include pollen, mold, dust mite, animal dander, air pollution, certain medications and exercise. The current drugs can effectively treat many people's symptoms, but as the lead author of the study, Dr. Ruth Sander said, "For many people with asthma, especially severe asthma, treatment is not 100% effective. Although the study is aimed at new treatments for allergic-related asthma, it still requires new therapies for allergies that are independent of allergies, and the steady increase in asthma cases and their fatalities and the shortage of drugs in some individuals make asthma research an important area of research."

A recent study at the University of Leicester, UK, investigated the role of specific proteins in asthma, called the high mobility group box 1 (HMGB1). Researchers hope their findings may pave the way for more effective treatment. HMGB1 is a chromatin protein, meaning that it helps to tissue DNA and regulate its transcription in the nucleus. It is secreted by immune cells (including monocytes, macrophages and dendritic cells) and promotes inflammatory responses.

Current studies use mucus and muscle tissue from mild to moderate patients with asthma. It is known that the smooth muscle in the airway has a significant contribution to the symptoms of asthma; it is overly contracted and the quality is increased, and the chemicals involved in the inflammatory response are released. "As far as we know, this is the first study to show that HMGB1 has a direct effect on stimulating the increased airway muscle contraction, and this study has led us closer to improving the treatment of patients with severe asthma," Dr. Sanders continued.

This is the early stage of the study of this new approach. However, it marks an important leap; by understanding the role of HMGB1 and its role in asthma, eventually we can take new interventions. By the way, Flarebio provides you with high-quality recombinant proteins like recombinant ECEL1 at competitive prices.

2017年3月2日星期四

Scientists have found that stimulating immune system may stop tumor growth

According to a new study, the discovery of chemicals in tumors may help to prevent tumor growth. Researchers at the University of Illinois at Chicago report that the increase in chemical cytokines called LIGHT in mice with colon cancer activates the natural killer T cells of the immune system and causes contraction of metastatic tumors in primary tumors and liver. The LIGHT is an immunostimulating chemical messenger that was previously found to have low levels of expression in patients with colon cancer metastases. The results were published in Cancer Research which has published studies on various recombinant proteins including recombinant horse proteins.

Colon cancer is the second leading cause of cancer death in the United States. "The current treatment is palliative for most patients with colon cancer who have spread to the liver," said Dr. Ajay Maker, Associate Professor of Surgery at UIC Medical School. "Although studies suggest that immunotherapy may be a form of promising way to treat advanced cancer, this treatment has not been very successful for advanced gastrointestinal metastasis."

Maker and his colleagues established colon cancer tumors in the mouse model, in which animals had a complete and unedited immune system. Once the tumor size was visible, the mice were randomized into two groups - one group turned on cytokine LIGHT in the tumor and the other group was used as a control group for comparison.

"We have demonstrated that the delivery of therapeutic immunostimulatory cytokines results in the transport of T cells into the tumor and becomes activated tumor killer cells," said Maker. "This activity is particularly exciting because it leads to a deep anti-tumor immune response having no other chemotherapy or intervention, manipulating our natural defense system to combat the tumor."

"We have not only found that LIGHT expression promotes tumor regression, and after further studies we have also identified specific types of T cells responsible for contracting tumors," said Maker, "These findings are strong and have great clinical potential." By the way, Flarebio provides you with superior recombinant proteins such as recombinant Nrg2 at competitive prices.

To use liver cells' own ability to burn liver fat

Swedish researchers are planning a clinical trial for nonalcoholic fatty liver and new therapies for type 2 diabetes - using liver cells' own ability to burn liver fat. In a study of 86 patients with varying degrees of fatty liver, researchers from the KTH Royal Institute of Technology's Life Sciences Research Center (SciLifeLab) and the University of Gothenburg found that the liver has the ability to burn and accumulate fat. The researchers suggested that a mixture could run this process. This result was published in the journal Molecular Systems Biology, which also publishes other studies on recombinant human proteins.

The researchers mapped metabolic changes in fat accumulation in 86 patients with hepatocytes and combined these data with the analysis of the liver tissue genome model to identify the precise metabolic changes experienced by different individual hepatocytes.

Adil Mardinoglu, the lead author of the study, is a systematic biologist at KTH and SciLifeLab and one of the researchers who previously linked NAFLD to low levels of antioxidant glutathione (GSH). The conceptual validation test showed that the treatment of human subjects by increasing the "cocktail" of fat oxidation and antioxidant synthesis would result in burning liver fat. "The team's metabolic modeling approach relies on data from the Swedish human protein profile that will be useful in many chronic liver disease studies," Mardinoglu said.

Based on the results of this study, improved intervention using material combination was designed. "This mixture may reduce the accumulation of fat in the liver," Mardinoglu said. "There is no such drug yet, and we plan to conduct further clinical trials later this year."

This method combines system biology with clinical medicine. "The results are exciting, and we are now designing a mixture that will promote the oxidation of fat and produce antioxidants in liver tissue," said Jan Borén, senior partner at Gothenburg University. The researchers believe that the mixture can also be used to treat alcoholic fatty liver and type 2 diabetes caused by liver fat accumulation. "Considering the common characteristics of NAFLD and diabetes usually coexisting and interacting with each other, the mixture may also be effective for people with diabetes," says Ulf Smith, a partner at Gothenburg University.

"I am delighted that the resources created through the work of human protein profiling can be used to analyze the clinical data of NAFLD and to guide the design of mixtures of clinical diseases," said Mathias Uhlén, program director for the Human Protein Atlas and co-author of the paper. Flarebio provides you with high-quality recombinant proteins like recombinant COLEC12.

2017年3月1日星期三

A potential drug target for obesity and related metabolic diseases

Guo Fumin Research team at Chinese Academy of Sciences, Shanghai Institute of Health revealed that the new function of hypothalamic aorticoprine (POMC) neurons activating transcription factor 4 (ATF4) to regulate energy balance and lipid metabolism of the body, providing a potential drug target for obesity and related metabolic diseases. Related research results have been published online recently in the journal Diabetes. By the way, this journal is also famous for its studies involving recombinant rat proteins.

The obesity of body is caused by imbalance of energy intake and energy consumption, and it plays a key regulatory role for body energy balance in central nervous system. In the hypothalamic arcuate nucleus, there are two types of neurons that regulate energy metabolism: one is the brain-related protein neurons that promote appetite; the other is the appetite-suppressing POMC neurons. POMC neurons inhibit the appetite by releasing the melanogenesis of the melanocortin, which on the other hand affects the energy dissipation of the body by regulating the excitability of the sympathetic nervous system.

The researchers specifically knocked out the ATF4 gene in mouse POMC neurons. Analysis showed that these knockout mice became thinner, the insulin sensitivity, leptin sensitivity and energy dissipation of the body increased and they could resist obesity induced by high-fat diet, insulin resistance and leptin resistance. Further study showed that ATF4 can bind to the promoter of the ATG5 gene to directly regulate its expression. The researchers also constructed double-knock mice of the ATF4 gene and the ATG5 gene in POMC neurons. Through its phenotypic analysis, it showed that double-knock mice can reverse the phenotype of ATF4 single-knockout mice. By the way, Flarebio provides you with recombinant proteins of good quality such as recombinant ITGB2.

Scientists have released pathogenic molecular mechanism of autism

Wu Bailin research group from Harvard University Boston Children's Hospital and Fudan University and Qiu Zilong research group from the Chinese Academy of Sciences Institute of Neuroscience completed a study to reveal the pathogenic molecular mechanism of autism. Related research results have been published online recently in the journal Molecular Psychiatry, which also has other studies on recombinant human proteins.

Autism is a complex hereditary syndrome and neuropsychiatric development of disease mostly in early childhood and there is no effective drug treatment. The study of basic and clinical research on autism and related animal models has become one of the hotspots in the field of medicine and neuroscience.

The researchers screened nine missense mutations of the DYRK1A gene in autistic patients and studied the function of Dyrk1a in the process of cell growth and cortical development by constructing mutant Dyrk1a. It was found that Dyrk1a plays an important role in the process of neurodevelopment, and the two nonsense mutations associated with autism have led to a functional loss of the DYRK1A protein.

The study suggests that the genetic mechanism associated with the disease is very complex, and the DYRK1A gene located on chromosome 21 is one of the autism candidate genes identified in recent years. The gene is well known for its role in Down's syndrome. Exon sequencing data show that autism patients also detected DYRK1A gene mutation, so the degree of correlation between this gene and autism has become an urgent scientific question which needs to be answered.

To this end, the researchers constructed the wild type, Dyrk1a_shRNA and nine mutant Dyrk1a plasmids of the gene. And the control group was expressed in mouse cortical neurons, rat hippocampal neurons and in vivo embryonic cortical cells, and they observed the growth and development of various types of cells.

The study firstly provides a functional study of neurodevelopmental-related mutations in DYRK1A, an important autistic candidate gene, which provides an important basis for further study of DYRK1A gene function and the pathogenesis of pathogenic molecules for autism. Flarebio offer high-quality recombinant proteins like recombinant CDH2 at competitive prices.

A vaccine that would fight all mosquito-borne diseases

Ars Technica has announced an important advancement in the field of vaccines: the National Institutes of Health (NIH) announced the launch of a vaccine phase I clinical trial that would fight all mosquito-borne diseases. According to research using recombinant human proteins, the vaccine, named AGS-v, is aimed at mosquito saliva rather than individual bacteria.

Scientists have been hoping for a vaccine to fight all the mosquitoes, and the UK Sik Biotechnology Group and NIH are pushing the dream to be a reality. The Sikh Group has developed an AGS-v vaccine for decades of exploration, which allows humans to immunize all diseases spread by mosquitoes. The company believes that the vaccine is equivalent to a "weapon". If the mosquito bites the vaccination of the vaccine, it will face death or the result of not being able to reproduce. AGS-v is not usually vaccinated to prevent a particular disease vaccine but creating a "whistle" for the mosquito saliva in the human body, that is, an immune system. When the mosquito remains saliva in the human body, the immune system will produce a similar allergic reaction to "destroy" pathogens in the body.

Scientists have been thinking about targeting mosquito saliva for some time. Mosquito saliva contains a variety of proteins, and the new vaccine is developed through the four kinds of proteins that usually can be found in mosquitoes. But at present, Sikh has not yet announced related data on the safety and efficacy of the vaccine.

Mosquito is the creature which kills the most humans, far more than the sum of the numbers of other biological killers. Mosquito-borne malaria is likely to be the greatest infectious disease of great threat to human history, and it can't be eradicated so far. This strange trick came up by US and British scientists makes the human immune system attack all foreign body injected by mosquito. If it is effective and feasible, it will become another milestone in the history of human medicine, meaning comparable to antibiotics. The human immune system has great potential, making use of it to destroy all kinds of incurable diseases in the future is more hopeful than medication. By the way, Flarebio provides you with superior recombinant proteins including recombinant ECE1 at competitive prices.

Autism-related gene variations improve brain evolution

Researchers at Yale University in the United States published a paper in the journal Public Library of Genetics that the genetic variation associated with autism may be a positive choice in the evolutionary process because these variations also help to increase human cognitive ability. More research through recombinant mouse proteins should be conducted.

In the long evolutionary process, humans produce a lot of genetic variation, and the effects of these variations on human genetic characteristics are positive and negative. Those who have a negative impact on human reproduction will be eliminated in the evolutionary process; and if the emergence of mutations can improve the chance of human survival, it will become a positive choice of human beings and be retained in the genome and be passed down generation by generation.

In this study, the researchers conducted a genome-wide association study of more than 5,000 cases of autism, and they analyzed the gene selection in human evolution. They found that genetic variation associated with autism is more of a positive choice in human evolutionary processes that are not only related to autism but also to human intelligence. For example, many autistic-related gene mutations identified by the researchers can enhance brain cell function and help to create new neurons.

Researchers point out that genetic variation that increases the risk of autism is a positive choice in the evolution of humans. This may make people feel unimaginable: why do a large number of autistic pathogenic gene mutations remain in the human genome? Why don't humans eliminate them in the evolutionary process? The reason is that these variations have a positive effect on human cognitive function, so it is actively chosen in the evolutionary process, and the cost is an increase in the risk of autism. Flarebio provides you with high-quality recombinant proteins like recombinant PIGR at good prices.